Innovation, in Expedition
Innovation, in Expedition
Innovation, in Expedition
01 / 03

Company

GENFLEET THERAPEUTICS

GenFleet Therapeutics is a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, founded in 2017 by veteran drug developers with the support from top-tier venture capital investors. Dedicated to serving significant unmet medical needs, GenFleet Therapeutics established its proprietary R&D platform based on the deep understanding of disease biology, translational medicine, as well as the research into latest biological mechanism of cancer pathways, tumor microenvironment and human immunoregulation. GenFleet's rich and diversified pipeline highlights multiple cutting-edge products with novel mechanisms and global IP.


10+

Leading-edge Pipeline

80%+

R&D Staff

5

R&D Functions

60%+

Staff with Master or Doctoral Degrees

2

Manufacturing Sites

xinwenliebiaobanner-897.jpg

Science

Since its inception in 2017, GenFleet has built up industry-leading capabilities and expertise in developing novel drug candidates - both small molecules and biologics. Its pipeline includes over 10 programs in development, many of which have entered clinical stages. 

0a1_06.jpg

Among them, the TGF-β R1 (transforming growth factor-β receptor 1) inhibitor has entered phase Ib/II clinical trial and boasts broad prospects of treating solid tumors with lower response rates to PD-1 inhibitors; the CDK9(cyclin-dependent kinase 9) inhibitor has been granted with IND approval in China and US, marking the beginning of the company's global multi-center clinical trial strategy;besides, GenFleet is the first Chinese company that moves RIPK1 inhibitor development into clinical stage.  In mid 2021, GenFleet also received IND approval to proceed with the clinical trials of its KRAS G12C inhibitor.

Careers

  • Resilience
  • Innovation
  • Empowerment
bahe2.jpg
0a1_10.jpg
weixintupian_20210322181233.jpg
weixintupian_20210722094641.jpg